
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences Inc. is demonstrating significant financial improvement, with upward revisions to its FY26 earnings per share (EPS) estimates reflecting reduced expenses and a growing share count, indicating effective cost management and business scaling. The company's revised price target of $9.20 highlights the potential for substantial growth as it capitalizes on the increasing adoption of its AI-powered ECG diagnostic solutions across various healthcare settings. Furthermore, the expansion of its average shares outstanding from 0.9 million to 3.2 million suggests robust engagement in equity financing, aligning with the company's ambitions to capture a substantial market share in cardiac diagnostics.
Bears say
HeartSciences Inc. faces a challenging financial outlook, as evidenced by a significant reduction in revenue estimates for FY2026-2027, dropping to $0.0 million and $0.4 million, respectively. Operating expenses remain substantial at $2.1 million, indicating a potential cash burn without a clear path to profitability amidst ongoing uncertainties. Additionally, numerous risks, including liquidity concerns, regulatory hurdles, and competitive pressures, further compound the negative outlook on the company's ability to successfully commercialize its AI-ECG diagnostic solutions.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares